Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.

von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.

Eur J Haematol. 2019 Feb;102(2):163-173. doi: 10.1111/ejh.13188. Epub 2019 Jan 7.

PMID:
30347469
2.

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.

Heine S, Kleih M, Giménez N, Böpple K, Ott G, Colomer D, Aulitzky WE, van der Kuip H, Silkenstedt E.

J Hematol Oncol. 2018 Sep 4;11(1):112. doi: 10.1186/s13045-018-0657-6.

3.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL).

Ann Oncol. 2017 Nov 1;28(11):2793-2798. doi: 10.1093/annonc/mdx500.

PMID:
28945881
4.

Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin.

Höring E, Staiger AM, Lenze D, Horn H, Vöhringer M, Steurer W, Aulitzky WE, Ott G.

Leuk Lymphoma. 2018 Jan;59(1):249-252. doi: 10.1080/10428194.2017.1330469. Epub 2017 Jun 5. No abstract available.

PMID:
28583033
5.

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

Höring E, Montraveta A, Heine S, Kleih M, Schaaf L, Vöhringer MC, Esteve-Arenys A, Roué G, Colomer D, Campo E, Ott G, Aulitzky WE, van der Kuip H.

Br J Haematol. 2017 May;177(4):557-561. doi: 10.1111/bjh.14571. Epub 2017 Mar 14.

PMID:
28295185
6.

An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis.

Staiger AM, Duppel J, Dengler MA, van der Kuip H, Vöhringer MC, Aulitzky WE, Rosenwald A, Ott G, Horn H.

Leuk Lymphoma. 2017 Aug;58(8):1922-1930. doi: 10.1080/10428194.2016.1263841. Epub 2016 Dec 6.

PMID:
27919179
7.

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.

Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, Sauer G, Aulitzky WE, van der Kuip H.

Cancer Res. 2016 May 15;76(10):2868-75. doi: 10.1158/0008-5472.CAN-15-2908. Epub 2016 Mar 24.

8.

A Temperature of 40 °C Appears to be a Critical Threshold for Potentiating Cytotoxic Chemotherapy In Vitro and in Peritoneal Carcinomatosis Patients Undergoing HIPEC.

Schaaf L, van der Kuip H, Zopf W, Winter S, Münch M, Mürdter TE, Thon KP, Steurer W, Aulitzky WE, Ulmer C.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S758-65. doi: 10.1245/s10434-015-4853-0. Epub 2015 Sep 8.

PMID:
26350370
9.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2015 May 1;33(13):1519.

PMID:
25547501
10.

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H.

Eur J Cancer. 2015 Jan;51(1):27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5.

PMID:
25459392
11.

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia.

Leukemia. 2015 May;29(5):1060-8. doi: 10.1038/leu.2014.335. Epub 2014 Dec 1.

PMID:
25434303
12.

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.

Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H.

Cell Death Dis. 2014 Jul 10;5:e1318. doi: 10.1038/cddis.2014.284.

13.

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.

Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vöhringer MC, Horn H, Ott G, Aulitzky WE, van der Kuip H.

Cell Death Dis. 2014 Jan 23;5:e1013. doi: 10.1038/cddis.2013.552.

14.

Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4.

Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE, van der Kuip H.

Cancer Res. 2013 Mar 1;73(5):1460-9. doi: 10.1158/0008-5472.CAN-12-2876. Epub 2013 Jan 9.

15.

Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin.

Schmid JO, Dong M, Haubeiss S, Friedel G, Bode S, Grabner A, Ott G, Mürdter TE, Oren M, Aulitzky WE, van der Kuip H.

Cancer Res. 2012 Nov 15;72(22):5824-32. doi: 10.1158/0008-5472.CAN-12-1201. Epub 2012 Sep 7.

16.

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME.

Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14.

17.

Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.

Dengler MA, Staiger AM, Gutekunst M, Hofmann U, Doszczak M, Scheurich P, Schwab M, Aulitzky WE, van der Kuip H.

PLoS One. 2011;6(9):e25139. doi: 10.1371/journal.pone.0025139. Epub 2011 Sep 20.

18.

p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.

Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, Aulitzky WE, van der Kuip H.

PLoS One. 2011 Apr 21;6(4):e19198. doi: 10.1371/journal.pone.0019198.

19.

Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial.

Stölzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhäuser M, Röllig C, Kramer M, Mohr B, Oelschlägel U, Schmitz N, Soucek S, Thiede C, Ehninger G, Schaich M; Study Alliance Leukemia.

Leukemia. 2011 Mar;25(3):420-8. doi: 10.1038/leu.2010.279. Epub 2010 Dec 7.

PMID:
21135859
20.

Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts.

Haubeiss S, Schmid JO, Mürdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE.

Mol Cancer. 2010 Jun 27;9:168. doi: 10.1186/1476-4598-9-168.

21.

Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.

Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H.

Cancer Res. 2009 Dec 15;69(24):9337-45. doi: 10.1158/0008-5472.CAN-09-0548.

22.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M.

J Clin Oncol. 2009 Sep 20;27(27):4548-54. doi: 10.1200/JCO.2008.19.8820. Epub 2009 Aug 24.

PMID:
19704068
23.

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE.

BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364.

24.

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Henkes M, van der Kuip H, Aulitzky WE.

Ther Clin Risk Manag. 2008 Feb;4(1):163-87.

25.

Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.

Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, van der Kuip H.

Oncogene. 2008 Jul 17;27(31):4380-4. doi: 10.1038/onc.2008.68. Epub 2008 Mar 24.

PMID:
18362889
26.

Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S.

Clin Cancer Res. 2007 Jun 1;13(11):3198-206.

27.

Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.

Schuler U, Bammer S, Aulitzky WE, Binder C, Böhme A, Egerer G, Sandherr M, Schwerdtfeger R, Silling G, Wandt H, Glasmacher A, Ehninger G.

Onkologie. 2007 Apr;30(4):185-91. Epub 2007 Mar 23.

PMID:
17396041
28.

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.

Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A.

Leukemia. 2007 Jun;21(6):1183-8. Epub 2007 Mar 22.

PMID:
17377585
29.

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).

Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC.

Ann Oncol. 2006 Oct;17(10):1546-52. Epub 2006 Aug 3.

PMID:
16888080
30.

Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.

van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE.

BMC Cancer. 2006 Apr 7;6:86.

31.

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.

Fritz P, Cabrera CM, Dippon J, Gerteis A, Simon W, Aulitzky WE, van der Kuip H.

Breast Cancer Res. 2005;7(3):R374-84. Epub 2005 Mar 21.

32.

Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death.

Moehring A, Wohlbold L, Aulitzky WE, van der Kuip H.

Cell Death Differ. 2005 Jun;12(6):627-36.

33.

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.

van der Kuip H, Wohlbold L, Oetzel C, Schwab M, Aulitzky WE.

Am J Pharmacogenomics. 2005;5(2):101-12. Review.

PMID:
15813673
34.

All common p210 and p190 Bcr-abl variants can be targeted by RNA interference.

Wohlbold L, van der Kuip H, Moehring A, Granot G, Oren M, Vornlocher HP, Aulitzky WE.

Leukemia. 2005 Feb;19(2):290-2. No abstract available.

PMID:
15565163
35.

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.

Blood. 2005 Feb 15;105(4):1652-9. Epub 2004 Sep 30.

PMID:
15459011
36.

[Immunotherapy for advanced renal cell carcinoma].

Aulitzky WE, Kaufmann M.

Urologe A. 2004 Jan;43(1):85-92; quiz 93. Review. German.

PMID:
15179984
37.

Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.

van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE.

Leuk Res. 2004 Apr;28(4):405-8.

PMID:
15109541
38.

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE.

Blood. 2003 Sep 15;102(6):2236-9. Epub 2003 May 15.

PMID:
12750174
39.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group.

Blood. 2002 Nov 1;100(9):3115-20.

PMID:
12384407
40.
41.

Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.

Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Göbel U, Kremens B, Fölsch UR, Aulitzky WE, Voûte PA, Zoubek A, Jürgens H.

Ann Oncol. 2001 Nov;12(11):1619-30.

PMID:
11822764
42.

Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.

Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE.

Cancer Res. 2001 Oct 15;61(20):7635-41.

43.

Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.

van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE.

Blood. 2001 Sep 1;98(5):1532-41.

PMID:
11520804
44.

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.

Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, Aulitzky WE.

Blood. 2000 Sep 1;96(5):1933-9.

PMID:
10961897
45.

The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.

Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE.

Clin Cancer Res. 2000 May;6(5):1958-68.

46.

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE.

Clin Cancer Res. 1999 Dec;5(12):3983-9.

47.

Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism.

Busse D, Busch FW, Schweizer E, Bohnenstengel F, Eichelbaum M, Fischer P, Schumacher K, Aulitzky WE, Kroemer HK.

Cancer Chemother Pharmacol. 1999;43(3):263-8.

PMID:
9923558
48.

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study.

Schuler M, Bruntsch U, Späth-Schwalbe E, Schrezenmeier H, Peschel C, Färber L, Burger KJ, Leissner J, Huber C, Aulitzky WE.

Eur J Cancer. 1998 Apr;34(5):754-6.

PMID:
9713286
49.

Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors.

Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, Huber C, Aulitzky WE.

Br J Haematol. 1998 Feb;100(2):295-303.

PMID:
9488616
50.

Spontaneous and interleukin-2-modulated cytokine release by bronchoalveolar cells in pulmonary malignancy.

Gaede KI, Zissel G, Schwuléra U, Struff WG, Lorenz J, Aulitzky WE, Zipfel P, Schrum S, Schlaak M, Huber C, Müller-Quernheim J.

Eur Cytokine Netw. 1997 Dec;8(4):395-400.

Supplemental Content

Loading ...
Support Center